Scarica l'app Stockscreener
1.41
0.00%
0.00
Precedente Chiudi:
$1.41
Aprire:
$1.41
Volume 24 ore:
203.65K
Relative Volume:
0.10
Capitalizzazione di mercato:
$245.72M
Reddito:
$250.00K
Utile/perdita netta:
$-24.15M
Rapporto P/E:
-1.3232
EPS:
-1.0656
Flusso di cassa netto:
$-12.40M
1 W Prestazione:
-8.44%
1M Prestazione:
-16.57%
6M Prestazione:
-39.48%
1 anno Prestazione:
-18.50%
Intervallo 1D:
$1.39
$1.46
Intervallo di 1 settimana:
$1.38
$1.5789
Portata 52W:
$1.32
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.41 | 245.72M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
501.23 | 127.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.07 | 90.25B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
788.26 | 81.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.12 | 51.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.92 | 41.85B | 5.76B | 514.49M | 1.10B | 4.4813 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-09 | Iniziato | Raymond James | Outperform |
| 2026-07-23 | Iniziato | Oppenheimer | Outperform |
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-26 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-09 | Iniziato | B. Riley Securities | Buy |
| 2025-12-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 11 October By Investing.com - Investing.com South Africa
Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com South Africa
Form 4 Palisade Bio Inc For: 11 October By Investing.com - Investing.com Nigeria
Palisade Bio director buys $28,800 in PALI stock By Investing.com - Investing.com Canada
Form 4 Palisade Bio Inc For: 10 October By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 10 October By Investing.com - Investing.com India
Palisade Bio (NasdaqCM:PALI) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com Nigeria
Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com Canada
Form 4 Palisade Bio Inc For: 7 October By Investing.com - Investing.com UK
Palisade Bio CEO John David Finley Settles 3.2M RSUs, Withholds 1.4M Shares for Taxes on Oct 6, 2026 - Kalkine Media
A director buys shares at $1.42 and $1.46 in Palisade Bio (PALI). - stocktitan.net
KALA BIO, Inc. (KALA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palisade Bio (Nasdaq:PALI)Stock Analysis - Simply Wall Street
Palisade Bio to Present Early PALI-2108 Clinical and Biomarker Data at UEG Week 2026 - Quiver Quantitative
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026 - GlobeNewswire Inc.
A bowel-disease drug showed a response within a week. Palisade Bio will present the findings in October. - Stock Titan
Palisade Bio, Inc. (PALI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Core AI Holdings Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency - manilatimes.net
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance - GlobeNewswire Inc.
The FDA cleared Palisade Bio’s Crohn’s trial application. First patient dosing is targeted for early 2027. - Stock Titan
Here's Why We're Not Too Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn Situation - simplywall.st
Palisade Bio (PALI) Advances 5.26% as Shares Test Key Resistance at $2.31Regression Channel - siam.in
Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Three September healthcare conferences will include Palisade Bio management - Stock Titan
Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan
Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView
FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeETF Inflow Streak - vinanet.vn
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail
Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia
Palisade Bio clears FDA for Phase 2 UC trial - scanx.trade
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Nigeria
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com
Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade
Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Canada
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com UK
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palisade Bio Inc Azioni (PALI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Williams Donald Allen | Director |
Oct 01 '26 |
Buy |
1.42 |
10,000 |
14,200 |
1,580,294 |
| Baltera Robert Jr. | Director |
Jul 09 '26 |
Buy |
1.96 |
25,000 |
48,900 |
461,904 |
| Baltera Robert Jr. | Director |
Jul 08 '26 |
Buy |
1.99 |
20,000 |
39,798 |
436,904 |
| Jones Mitchell Lawrence | Officer |
Jul 07 '26 |
Proposed Sale |
2.04 |
53,000 |
108,120 |
0 |
| Finley John David | Officer |
Jul 07 '26 |
Proposed Sale |
2.07 |
146,798 |
303,343 |
0 |
| Jones Mitchell Lawrence | Chief Medical Officer |
Jul 07 '26 |
Sale |
2.05 |
51,880 |
106,536 |
94,009 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Option Exercise |
0.70 |
133 |
93 |
217,688 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Sale |
2.07 |
146,798 |
303,343 |
217,555 |
| Baltera Robert Jr. | Director |
Jul 07 '26 |
Buy |
2.03 |
30,000 |
61,044 |
416,904 |
| Baltera Robert Jr. | Director |
Jul 06 '26 |
Buy |
2.05 |
20,000 |
41,040 |
386,904 |
3.80%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):